Alterity files 2026 report, readies ATH434 Phase 3

ALTERITY THERAPEUTICS LTD (ATHE) reports that it has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the U.S. Securities and Exchange Commission.

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD (ATHE) reports that it has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the U.S. Securities and Exchange Commission. The report and related XBRL interactive data are available on the company’s website, and shareholders can request a hard copy free of charge.

Alterity describes itself as a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, following clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data from an open-label Phase 2 trial in advanced MSA.

Filing Explained

This August 31 Form 6-K, an interim report, states that the report is incorporated by reference into three Form S-8 and four Form F-3 registration statements, making its furnished information part of those registration materials.

Key Terms

Form 20-F, XBRL interactive data, Multiple System Atrophy (MSA), Phase 3 pivotal trial, +2 more

6 terms

Form 20-F regulatory

"filed its Annual Report on Form 20-F containing audited consolidated"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

XBRL interactive data financial

"The company has also filed the XBRL interactive data with the SEC"

Multiple System Atrophy (MSA) medical

"developing disease modifying therapies in Multiple System Atrophy (MSA)"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled Phase 2 clinical trial medical

"lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind"

open label Phase 2 clinical trial medical

"has further reported positive data in its open label Phase 2 clinical"

FAQ

What did ALTERITY THERAPEUTICS LTD (ATHE) announce in this Form 6-K?

Alterity Therapeutics announced it has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the SEC, and that the report and XBRL data are available on its website.

Where can ATHE investors access Alterity Therapeutics’ 2026 Form 20-F and XBRL data?

Investors can access the Form 20-F and the XBRL interactive data via Alterity Therapeutics’ website at https://alteritytx.com, and shareholders may request a hard copy of the annual report free of charge.

What is the therapeutic focus of Alterity Therapeutics (ATHE)?

Alterity Therapeutics is focused on neurodegenerative diseases, specifically developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders, supported by its drug discovery platform targeting underlying neurological pathology.

What clinical progress has Alterity Therapeutics (ATHE) reported for ATH434?

Alterity states that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and that it has reported positive data from an open-label Phase 2 trial in participants with advanced MSA.

What are the next clinical steps for Alterity Therapeutics’ lead asset ATH434 (ATHE)?

Alterity reports it is preparing to initiate a Phase 3 pivotal trial of ATH434 in Multiple System Atrophy, a rare and rapidly progressive neurodegenerative disease.

Who authorized this announcement by Alterity Therapeutics (ATHE)?

The announcement was authorized by David Stamler, who is identified as the CEO and Managing Director of Alterity Therapeutics Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 06:58 AM Accepted by SEC EDGAR 08/31/2026 - 06:01 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Alterity Therapeutics Filed Form 20-F and XBRL data with SEC

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: August 31, 2026

2

Exhibit 99.1

Alterity Therapeutics Filed Form 20-F and XBRL data with the SEC

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 August 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year ended June 30, 2026 with the US Securities and Exchange Commission (SEC). The annual report is available on the company website https://alteritytx.com. Shareholders may receive a hard copy of the annual report free of charge upon request.

The company has also filed the XBRL interactive data with the SEC and this is available via the company website at https://alteritytx.com/press-releases .

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional Information

This announcement was authorized by David Stamler, CEO and Managing Director of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 10.7 KB